-- Company to host a live webcast event with an expert panel of clinicians during EHA2025 -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining ...
Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to Approved Autologous Therapies Presentation ...
Day One Biopharmaceuticals (DAWN) announced three-year results from the OJEMDA pivotal Phase 2 FIREFLY-1 trial in an oral presentation at the 30th ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback